• FDA granted priority review to CorMedix's application for Rezzayo to prevent invasive fungal disease, with a decision targeted for Q1 2027.
• A potential promotional launch is targeted for the second half of 2027, subject to approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.